Yang Xiaochen, Wu Jiong, Lu Jingsong, Liu Guangyu, Di Genhong, Chen Canming, Hou Yifeng, Sun Menghong, Yang Wentao, Xu Xiaojing, Zhao Ying, Hu Xin, Li Daqiang, Cao Zhigang, Zhou Xiaoyan, Huang Xiaoyan, Liu Zhebin, Chen Huan, Gu Yanzi, Chi Yayun, Yan Xia, Han Qixia, Shen Zhenzhou, Shao Zhimin, Hu Zhen
Department of Breast Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Tissue Bank, Department of Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.
PLoS One. 2015 Apr 30;10(4):e0125571. doi: 10.1371/journal.pone.0125571. eCollection 2015.
The genetic etiology of hereditary breast cancer has not been fully elucidated. Although germline mutations of high-penetrance genes such as BRCA1/2 are implicated in development of hereditary breast cancers, at least half of all breast cancer families are not linked to these genes. To identify a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population, we performed an analysis of germline mutations in 2,165 coding exons of 152 genes associated with hereditary cancer using next-generation sequencing (NGS) in 99 breast cancer patients from families of cancer patients regardless of cancer types. Forty-two deleterious germline mutations were identified in 21 genes of 34 patients, including 18 (18.2%) BRCA1 or BRCA2 mutations, 3 (3%) TP53 mutations, 5 (5.1%) DNA mismatch repair gene mutations, 1 (1%) CDH1 mutation, 6 (6.1%) Fanconi anemia pathway gene mutations, and 9 (9.1%) mutations in other genes. Of seven patients who carried mutations in more than one gene, 4 were BRCA1/2 mutation carriers, and their average onset age was much younger than patients with only BRCA1/2 mutations. Almost all identified high-penetrance gene mutations in those families fulfill the typical phenotypes of hereditary cancer syndromes listed in the National Comprehensive Cancer Network (NCCN) guidelines, except two TP53 and three mismatch repair gene mutations. Furthermore, functional studies of MSH3 germline mutations confirmed the association between MSH3 mutation and tumorigenesis, and segregation analysis suggested antagonism between BRCA1 and MSH3. We also identified a lot of low-penetrance gene mutations. Although the clinical significance of those newly identified low-penetrance gene mutations has not been fully appreciated yet, these new findings do provide valuable epidemiological information for the future studies. Together, these findings highlight the importance of genetic testing based on NCCN guidelines and a multi-gene analysis using NGS may be a supplement to traditional genetic counseling.
遗传性乳腺癌的遗传病因尚未完全阐明。虽然BRCA1/2等高外显率基因的种系突变与遗传性乳腺癌的发生有关,但至少一半的乳腺癌家族与这些基因无关。为了在中国人群中确定遗传性乳腺癌的全面遗传因素谱,我们对99例来自癌症患者家庭(不考虑癌症类型)的乳腺癌患者,使用下一代测序(NGS)技术分析了与遗传性癌症相关的152个基因的2165个编码外显子中的种系突变。在34例患者的21个基因中鉴定出42个有害种系突变,包括18个(18.2%)BRCA1或BRCA2突变、3个(3%)TP53突变、5个(5.1%)DNA错配修复基因突变、1个(1%)CDH1突变、6个(6.1%)范可尼贫血途径基因突变和9个(9.1%)其他基因突变。在携带多个基因突 变的7例患者中,4例是BRCA1/2突变携带者,他们的平均发病年龄比仅携带BRCA1/2突变的患者年轻得多。除了两个TP53和三个错配修复基因突变外,这些家族中几乎所有已鉴定出的高外显率基因突变都符合美国国立综合癌症网络(NCCN)指南中列出的遗传性癌症综合征的典型表型。此外,对MSH3种系突变的功能研究证实了MSH3突变与肿瘤发生之间的关联,分离分析表明BRCA1和MSH3之间存在拮抗作用。我们还鉴定出许多低外显率基因突变。虽然这些新鉴定出的低外显率基因突变的临床意义尚未得到充分认识,但这些新发现确实为未来的研究提供了有价值的流行病学信息。总之,这些发现突出了基于NCCN指南进行基因检测的重要性,使用NGS进行多基因分析可能是对传统遗传咨询的一种补充。